Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer (Q24188046)

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26544085 AND SRC:MED&resulttype=core&format=json

6 June 2020

J B Court

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26544085 AND SRC:MED&resulttype=core&format=json

6 June 2020

Howard G Kynaston

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26544085 AND SRC:MED&resulttype=core&format=json

6 June 2020

Malcolm Mason

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26544085 AND SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

6 June 2020

publication date

7 November 2015

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26544085 AND SRC:MED&resulttype=core&format=json

6 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26544085 AND SRC:MED&resulttype=core&format=json

6 June 2020

page(s)

CD003231

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26544085 AND SRC:MED&resulttype=core&format=json

Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study

6 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003231.PUB2

Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003231.PUB2

Intravesical chemotherapy and immunotherapy for superficial tumors Basic mechanism of action and future direction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003231.PUB2

Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003231.PUB2

Factors affecting recurrence and progression in superficial bladder tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003231.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003231.PUB2

Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003231.PUB2

A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003231.PUB2

7 January 2021

Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003231.PUB2

7 January 2021

A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003231.PUB2

7 January 2021

A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003231.PUB2

7 January 2021

A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003231.PUB2

7 January 2021

Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003231.PUB2

7 January 2021

Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003231.PUB2

7 January 2021

Intravesical Thiotepa versus Mitomycin C in Patients with TA, T1 and TIS Transitional Cell Carcinoma of the Bladder: A Phase III Prospective Randomized Study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003231.PUB2

7 January 2021

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003231.PUB2

7 January 2021

Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisati

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003231.PUB2

7 January 2021

Adjuvant Intravesicular Pharmacotherapy for Superficial Bladder Cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003231.PUB2

7 January 2021

Instillation of mitomycin C and doxorubicin in the prevention of recurrent superficial (Ta-T1) bladder cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003231.PUB2

7 January 2021

Intravesical Chemotherapy (Mitomycin C) versus Immunotherapy (Bacillus Calmette-Guérin) in Superficial Bladder Cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003231.PUB2

7 January 2021

4'-Epidoxorubicin versus Mitomycin C Intravesical Chemoprophylaxis of Superficial Bladder Cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003231.PUB2

7 January 2021

Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003231.PUB2

7 January 2021

10.1002/14651858.CD003231.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26544085 AND SRC:MED&resulttype=core&format=json

6 June 2020

1 reference